Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 6/20 | 0.85 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.85 |
| ▸ | AVPR1B known ✓ | P47901 | 4/20 | 0.85 |
| ▸ | OXTR | P30559 | 9/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL13575732 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL13775933 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22510 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29317578 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL14027607 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL204511 | 0.98 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| WO-2022081993-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| WO-2021119439-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF BCL-2 AND BCL-XL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3820534-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | disclosed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2015013690-A1 | VASOPRESSIN-2 RECEPTOR AGONISTS | FERRING B.V. (NL) | 2015-01-29 | — | — | WO | disclosed |
| US-8167870-B2 | Apparatus and method for the controlled hydrodistention of the urinary bladder | SHEHATA SOBHY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100016839-A1 | APPARATUS AND METHOD FOR THE CONTROLLED HYDRODISTENTION OF THE URINARY BLADDER | SHEHATA SOBHY | 2010-01-21 | — | — | US | disclosed |
| US-7615046-B2 | Apparatus and method for the controlled hydrodistention of the urinary bladder | SHEHATA SOBHY | 2009-11-10 | — | — | US | disclosed |
| CN-101553210-A | Method and system for delivering a drug via inhalation | NEXT SAFETY INC (US) | 2009-10-07 | — | — | CN | disclosed |
| US-20080172041-A1 | Apparatus and method for the controlled hydrodistention of the urinary bladder | SHEHATA SOBHY | 2008-07-17 | — | — | US | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| US-5985835-A | HIGH-PURITY DESMOPRESSIN PRODUCED IN SINGLE BATCHES OF SUBSTANTIAL SIZE | FERRING B.V. (NL) | 1999-11-16 | — | — | US | disclosed |
| WO-1995018602-A1 | ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP) | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | AVPR1A 4759/4885AVPR2 4856/4885AVPR1B 4755/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | AVPR1A 4194/4885AVPR2 3546/4885AVPR1B 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.